

CURRICULUM VITAE



PERSONAL INFORMATION

CICCONE, LUCIA PIA

Address Via Antella, 58, 50012 Bagno a Ripoli (FI) ITALY
Phone +39 055 6936736
E-mail luciapia.ciccone@uslcentro.toscana.it
Nationality Italiana
Date of Birth 28/09/1989

WORK EXPERIENCE

01/08/2024 – present
Azienda USL Toscana Centro, Florence
Santa Maria Annunziata Hospital
Via Antella, 58, 50012 Bagno a Ripoli (FI) ITALY
Oncological Department - Radiation Oncology Unit

17/01/2022 – 30/07/2024
CNAO Foundation (National Center for Oncological
Hadrontherapy)
Via E. Borloni, 1 - 27100 Pavia (PV) Italy
Clinical department – Neuro-Oncology Unit

EDUCATION AND TRAINING

29/12/2017-29/12/2021
AOU Careggi - DSBSC "Mario Serio" University of Florence, Florence
(Italy)
Radiation Oncology Unit
Resident in Radiation Oncology

26/07/2017 - present
Listed in the Register of Physician and Surgeons of Foggia

2017/1
Qualified to exercise the profession Physician and Surgeons
University of Florence, Florence (Italy)

2008 - 2017

Degree in Medicine (M.D.-Medical Doctor)
University of Florence, Florence (Italy)

2003 - 2008

High School Diploma

Liceo statale "Maria Immacolata" indirizzo scientifico-tecnologico
San Giovanni Rotondo, Foggia, Italy

PERSONAL SKILLS AND COMPETENCES

MOTHER TONGUE

ITALIAN

OTHER LANGUAGES

ENGLISH

- Reading skills Excellent
- Writing skills Excellent
- Verbal skills Good

ORGANISATIONAL SKILLS AND COMPETENCES

EXPERIENCE IN NEURO-ONCOLOGY
MANAGEMENT OF CANCER PATIENTS WITHIN
MULTIDISCIPLINARY TEAMS
WRITING OF RESEARCH PROJECTS
CONDUCTION OF CLINICAL TRIALS

TECHNICAL SKILLS AND COMPETENCES ANNEXES

OFFICE PACKAGE
RESEARCHES IN PUBLIC DATABASES
BIO-STATISTICAL SOFTWARE (SPSS, MedCalc)
PEER REVIEWING ACTIVITY
SCIENTIFIC PUBLICATIONS

PEER REVIEWING ACTIVITY

From October 2020 - present
Critical Reviews in Oncology/Hematology (ISSN: 1040-8428)
American Journal of Clinical Oncology (ISSN: 0277-3732)
La Radiologia Medica (ISSN: 1826-6983)
Urologic Oncology: Seminars and Original Investigations (ISSN: 1078-1439)

SCIENTIFIC AFFILIATIONS

AIRO (Italian Association of Clinical Oncology and Radiotherapy)
ESTRO (European Society Radiation Oncology)

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 relativo alla protezione delle persone fisiche con riguardo al trattamento dei dati personali. Tale documento ha funzione di autocertificazione ai sensi del D.P.R. n. 445 del 28/12/2000.

Firenze, 02/08/2025



SCIENTIFIC PUBLICATIONS

1. Charged particle radiotherapy for thyroid cancer. A systematic review
Ciccone LP, Franzetti J, Bonora M, Ronchi S, Camarda AM, Charalampopoulou A, Facoetti A, Bazani A, Magro G, Vischioni B, Locati LD, Licitra L, Sauerwein WAG, Orlandi E.
Crit Rev Oncol Hematol. 2024 Oct;202:104463. doi: 10.1016/j.critrevonc.2024.104463
<https://www.sciencedirect.com/science/article/pii/S1040842824002063?via%3Dihub>
2. Heavy Ion Therapy in Brain Tumors. In: Lopci, E., Mansi, L. (eds) Advanced Imaging and Therapy in Neuro-Oncology. Springer, Cham.
Riva G, **Ciccone LP**, Iannalfi A., Orlandi E.
doi:10.1007/978-3-031-59341-3_8
https://link.springer.com/chapter/10.1007/978-3-031-59341-3_8
3. A dosiomics approach to treatment outcome modeling in carbon ion radiotherapy for skull base chordomas
Parrella G, Annunziata S, Morelli L, Molinelli S, Magro G, Ciocca M, Riva G, **Ciccone LP**, Iannalfi A, Paganelli C, Orlandi E, Baroni G.
Phys Med. 2024 Aug;124:103421. doi: 10.1016/j.ejmp.2024.103421.
[https://www.physicamedica.com/article/S1120-1797\(24\)00216-3/fulltext](https://www.physicamedica.com/article/S1120-1797(24)00216-3/fulltext)
4. Proton therapy for intracranial meningioma: a single-institution retrospective analysis of efficacy, survival and toxicity outcomes.
Iannalfi A, Riva G, Lillo S, **Ciccone LP**, Fontana G, Molinelli S, Trombetta L, Ciocca M, Imperato S, Pecorilla M, Orlandi E.
Neurooncol 169, 683–692 (2024). doi: 10.1007/s11060-024-04751-x
<https://link.springer.com/article/10.1007/s11060-024-04751-x>
5. Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Camerini A, Mazzoni F, Scotti V, Tibaldi C, Sbrana A, Calabrò L, Caliman E, **Ciccone LP**, Bernardini L, Graziani J, Grosso MA, Chella A, Allegrini G, Amoroso D, Baldini E.
J Clin Med. 2024 Jun 21;13(13):3642. doi: 10.3390/jcm13133642.
<https://www.mdpi.com/2077-0383/13/13/3642>
6. 1182: Deep learning-based multi-modal approach for predicting brain radionecrosis after proton therapy
Seetha, ST, Fontana G, Bazani A, Riva G, Molinelli S, Goodyear CA, **Ciccone LP**, Iannalfi A, Orlandi E.
Radiotherapy and Oncology, Volume 194, S5027 - S5030
[https://www.thegreenjournal.com/article/S0167-8140\(24\)01634-7/abstract](https://www.thegreenjournal.com/article/S0167-8140(24)01634-7/abstract)
7. 1917: multimodal imaging in protontherapy: accuracy in contouring of organs at risk in skull base chordoma
Anemoni L, Imperato S, Iannalfi A, Riva G, **Ciccone LP**, Orlandi E, Preda L, Paganelli C, Morelli L, Tampellini S, Piazzolla ME.
Radiotherapy and Oncology, Volume 194, S5990 - S5992
[https://www.thegreenjournal.com/article/S0167-8140\(24\)02227-8/abstract](https://www.thegreenjournal.com/article/S0167-8140(24)02227-8/abstract)
8. 667: LETd-based proton-therapy optimization strategy for brainstem sparing in neuro-oncological patients

- Molinelli S, Vai A, Magro G, Riva G, Russo S, Bazani A, **Ciccone LP**, Iannalfi A, Orlandi E, Ciocca M. Radiotherapy and Oncology, Volume 194, S4602 - S4605
[https://www.thegreenjournal.com/article/S0167-8140\(24\)01226-X/abstract](https://www.thegreenjournal.com/article/S0167-8140(24)01226-X/abstract)
9. 1872: Apparent diffusion coefficient maps as early biomarker for carbon ion RT in adenoid cystic carcinoma
Fontana G, Bonora M, Donatelli A, Vischioni B, Ronchi S, Ingargiola R, Camarda AM, Lillo S, Molinelli S, Russo S, Vitolo V, Fiore MR, Iannalfi A, Barcellini A, Riva G, **Ciccone LP**, Chalaszczyk A, Rotondi M, Franzetti J, Colombo F, Ciocca M, Preda L, Imparato S, Orlandi E.
Radiotherapy and Oncology, Volume 194, S5090 - S5092
[https://www.thegreenjournal.com/article/S0167-8140\(24\)02187-X/abstract](https://www.thegreenjournal.com/article/S0167-8140(24)02187-X/abstract)
 10. 1262: NTCP model predicting temporal lobe necrosis in skull-base tumors treated with proton therapy
Fontana G, Fiorina E, Molinelli S, Riva G, Vai A, **Ciccone LP**, Iannalfi A, Orlandi E.
Radiotherapy and Oncology, Volume 194, S4460 - S4463
[https://www.thegreenjournal.com/article/S0167-8140\(24\)01695-5/abstract](https://www.thegreenjournal.com/article/S0167-8140(24)01695-5/abstract)
 11. 2271: Telemedicine clinical trial on survivors following hadrontherapy: preliminary results (NCT05947149)
Camarda AM, Tinelli C, **Ciccone LP**, Facchinetti N, Serra F, Iannalfi A, Riva G, Vischioni B, Bonora M, Ronchi S, Ingargiola R, Lillo S, Licitra L, Orlandi E.
Radiotherapy and Oncology, Volume 194, S2746 - S2750
[https://www.thegreenjournal.com/article/S0167-8140\(24\)02501-5/abstract](https://www.thegreenjournal.com/article/S0167-8140(24)02501-5/abstract)
 12. The clinical roadmap in a dual-beam hadrontherapy centre: tumour-based and patient-tailored selection criteria, management of range uncertainties and oncological patient pathway
Orlandi E, Lillo S, Camarda AM, Ronchi S, Chalaszczyk A, **Ciccone LP**, Rotondi M, Bonora M, Barcellini A.
Health Technol. 14, 1043–1050 (2024). <https://doi.org/10.1007/s12553-024-00865-4>
<https://link.springer.com/article/10.1007/s12553-024-00865-4#citeas>
 13. The role of particle radiotherapy in the treatment of skull base tumors
Iannalfi A, Riva G, **Ciccone LP**, Orlandi E.
Front. Oncol. 13:1161752. doi: 10.3389/fonc.2023.1161752
<https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1161752/full>
 14. PO-1126 Effectiveness and safety of proton therapy for brain meningiomas: a monocentric experience
Ciccone LP, Riva G, Bianchi SP, Rotondi M, Russo S, Iannalfi A, Orlandi E.
Radiotherapy and Oncology, Volume 182, S900 - S901
[https://www.thegreenjournal.com/article/S0167-8140\(23\)09123-5/abstract](https://www.thegreenjournal.com/article/S0167-8140(23)09123-5/abstract)
 15. PO-1131 Proton and carbon ion therapy for intracranial meningioma after previous brain radiotherapy
Riva G, **Ciccone LP**, Bianchi SP, Russo S, Iannalfi A, Orlandi E
Radiotherapy and Oncology, Volume 182, S904 - S905
[https://www.thegreenjournal.com/article/S0167-8140\(23\)09128-4/abstract](https://www.thegreenjournal.com/article/S0167-8140(23)09128-4/abstract)
 16. Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial
Camerini A, Del Conte A, Pezzuto A, Scotti V, Facchinetti F, **Ciccone LP**, Perna M, Sartori G, Puccetti C, Ricci A, Santo A, Tiseo M, Amoroso D.

17. 1041P Efficacy and safety of chemotherapy after progression on immunotherapy: Results of a multicenter retrospective observational trial
Camerini A, Mazzone F, Scotti V, Tibaldi C, Sbrana A, Calabrò L, Caliman E, **Ciccone LP**, Grosso MA, Chella A, Amoroso D, Baldini E.
Annals of Oncology Vol. 33 Supplement S1031 Published in issue: September 2022 doi: 10.1016/j.annonc.2022.07.1167
[https://www.annalsofoncology.org/article/S0923-7534\(22\)03018-6/fulltext](https://www.annalsofoncology.org/article/S0923-7534(22)03018-6/fulltext)
18. Tumor-Associated Macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer.
Loi M, Salvatore G, Sottili M, Calosi L, Desideri I, Becherini C, Salvestrini V, **Ciccone LP**, Stocchi G, Meattini I, Francolini G, Mangoni M, Livi L.
Clin Transl Oncol. 2022 Jul;24(7):1395-1402. doi: 10.1007/s12094-022-02785-z.
<https://link.springer.com/article/10.1007/s12094-022-02785-z>
19. Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719)
Francolini G, Detti B, Di Cataldo V, Garlatti P, Aquilano M, Allegra A, Lucidi S, Cerbai C, **Ciccone LP**, Salvestrini V, Stocchi G, Guerrieri B, Visani L, Loi M, Desideri I, Mangoni M, Meattini I, Livi L.
Radiol Med. 2022 Aug;127(8):912-918. doi: 10.1007/s11547-022-01511-7
<https://link.springer.com/article/10.1007/s11547-022-01511-7>
20. Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275)
Francolini G, Loi M, **Ciccone LP**, Detti B, Di Cataldo V, Pinzani P, Salvianti F, Salvatore G, Sottili M, Santini C, Frosini G, Visani L, Burchini L, Mattioli C, Allegra AG, Valzano M, Cerbai C, Aquilano M, Salvestrini V, Desideri I, Mangoni M, Meattini I, Livi L.
Med Oncol. 2022 Jun 10;39(8):119. doi: 10.1007/s12032-022-01756-2.
<https://link.springer.com/article/10.1007/s12032-022-01756-2>
21. Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833).
Desideri I, Lucidi S, Francolini G, Meattini I, **Ciccone LP**, Salvestrini V, Valzano M, Morelli I, Angelini L, Scotti V, Bonomo P, Greto D, Terziani F, Becherini C, Visani L, Livi L. Med Oncol. 2022 Jun 6;39(8):113. doi: 10.1007/s12032-022-01723-x.
<https://link.springer.com/article/10.1007/s12032-022-01723-x>
22. OC-0605 Early outcomes of a randomized trial of SBRT and Abiraterone in mCPRC: ARTO trial NCT03449719
Francolini G, Detti B, Di Cataldo V, Caini S, Alitto AR, Parisi S, Demofonti C, Bruni A, Ingrosso G, Timon G, Tagliagambe A, Aquilano M, **Ciccone LP**, Salvestrini V, Frosini G, Cerbai C, Allegra A, Burchini L, Desideri I, Mangoni M, Meattini I, Livi L.
Radiotherapy and Oncology, Vol 170, Suppl 1, S530-S531, May 01, 2022. doi: 10.1016/S0167-8140(22)02627-5
[https://www.thegreenjournal.com/article/S0167-8140\(22\)02627-5/fulltext#relatedArticles](https://www.thegreenjournal.com/article/S0167-8140(22)02627-5/fulltext#relatedArticles)

23. PD-0411 Predictive factors of late GU toxicity after Cyberknife re-irradiation for locally recurrent PCa
 Francolini G, Cerbai C, Loi M, Di Cataldo V, Detti B, Simontacchi G, **Ciccone LP**, Masi L, Doro R, Allegra A, Salvestrini V, Mattioli C, Frosini G, Burchini L, Aquilano M, Stocchi G, Desideri I, Livi L.
 Radiotherapy and Oncology, Vol 170, Suppl 1, S354, May 01, 2022. doi: 10.1016/S0167-8140(22)02846-8
[https://www.thegreenjournal.com/article/S0167-8140\(22\)02846-8/fulltext](https://www.thegreenjournal.com/article/S0167-8140(22)02846-8/fulltext)

24. PO-1324 Accelerated hypofractionation with SIB-IMRT in Anal Cancer: assessment of efficacy and toxicity
 Lucidi S, Bertini N, Loi M, Bonomo P, Francolini G, Greto D, Simontacchi G, Galardi A, Marrazzo L, Allegra A, Guerrieri B, Scoccimarro E, Mariotti M, Carnevale MG, Stocchi G, **Ciccone LP**, Peruzzi A, Lorenzetti V, Talamonti C, Pallotta S, Mangoni M, Livi L.
 Radiotherapy and Oncology, Vol 170, Suppl 1, S1118-S1120, May 01, 2022. doi:10.1016/S0167-8140(22)03288-1
[https://www.thegreenjournal.com/article/S0167-8140\(22\)03288-1/fulltext](https://www.thegreenjournal.com/article/S0167-8140(22)03288-1/fulltext)

25. PO-1363 Detection rate of 68Ga-PSMA PET/CT from a prospective study: PSICHE trial (NCT05022914)
 Francolini G, Di Cataldo V, Detti B, Allegra A, Burchini L, **Ciccone LP**, Cerbai C, Mattioli C, Frosini G, Guerrieri B, Aquilano M, Salvestrini V, Chiti A, Sollini M, Simontacchi G, Desideri I, Livi L.
 Radiotherapy and Oncology, Vol 170, Suppl 1, S1157-S1158, May 01, 2022 doi: 10.1016/S0167-8140(22)03327-8
[https://www.thegreenjournal.com/article/S0167-8140\(22\)03327-8/fulltext](https://www.thegreenjournal.com/article/S0167-8140(22)03327-8/fulltext)

26. Stereotactic or conventional radiotherapy for macroscopic prostate bed recurrence: a propensity score analysis.
 Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Gandini S, Corso F, **Ciccone LP**, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Desideri I, D'Angelillo RM, Masi L, Ingrosso G, Di Staso M, Mazzeo E, Trippa F, Lohr F, Bruni A, Livi L.
 Radiol Med. 2022 Apr;127(4):449-457. doi: 10.1007/s11547-022-01465-w.
<https://link.springer.com/article/10.1007/s11547-022-01465-w>

27. Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.
 Francolini G, **Ciccone LP**, Livi L.
 Eur Urol. 2022 Apr;81(4):e98-e99. doi: 10.1016/j.eururo.2021.11.034.
<https://www.sciencedirect.com/science/article/pii/S0302283821022648?via%3Dihub>

28. Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years
 Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Masi L, Doro R, Scoccimarro E, Bellini C, Aquilano M, Allegra AG, Peruzzi A, Guerrieri B, Morelli I, Valzano M, **Ciccone LP**, Salvestrini V, Desideri I, Livi L.
 Clin Oncol (R Coll Radiol). 2022 Jan;34(1):50-56. doi: 10.1016/j.clon.2021.11.002
[https://www.clinicaloncologyonline.net/article/S0936-6555\(21\)00421-0/fulltext](https://www.clinicaloncologyonline.net/article/S0936-6555(21)00421-0/fulltext)

29. Correction to: Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy facility

- Desideri I, Francolini G, Ciccone LP, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
Support Care Cancer. 2021 Nov 9:1–2. doi: 10.1007/s00520-021-06665-0
<https://link.springer.com/article/10.1007%2Fs00520-021-06665-0>
30. Pattern of Recurrence After Stereotactic Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-Institutional Retrospective Analysis
Francolini G, Bellini C, Di Cataldo V, Detti B, Bruni A, Alicino G, Triggiani L, La Mattina S, D'Angelillo RM, Demofonti C, Mazzola R, Cuccia F, Alongi F, Aquilano M, Allegra AG, **Ciccone LP**, Burchini L, Salvestrini V, Morelli I, Frosini G, Desideri I, Livi L.
Clinical Oncology, 2021, doi: 10.1016/j.clon.2021.09.014
www.sciencedirect.com/science/article/pii/S0936655521003496
 31. PO-1087 Hypofractionated radiotherapy for breast cancer orbital lesion: a multicentric series of 35 patients
Desideri I, **Ciccone LP**, Piperno G, Augugliaro M, Jereczek-Fossa BA, Navarria P, Dominici L, Scorsetti M, Salvestrini V, Riva G, Di Cataldo V, Visani L, Loi M, Meattini I, Livi L.
Radiotherapy and Oncology, Vol161, Suppl 1,S904-S906 doi: 10.1016/S0167-8140(21)07538-1
<https://www.sciencedirect.com/science/article/pii/S0167814021075381>
 32. PO-0998 Dosimetric predictors of patient-reported taste alteration in head and neck cancer: a cohort study
Scoccimarro E, **Ciccone LP**, Caini S, Aquilano M, Peruzzi A, Becherini C, Livi L, Desideri I, Bonomo P.
Radiotherapy and Oncology, Vol161, Suppl 1,S830-S831, doi:10.1016/S0167-8140(21)07449-1
<https://www.sciencedirect.com/science/article/pii/S0167814021074491>
 33. PO-1316 Stereotactic radiotherapy in recurrent prostate cancer after postoperative or definitive irradiation
Francolini G, Loi M, Di Cataldo V, Detti B, Stocchi G, Allegra AG, Bellini C, Aquilano M, **Ciccone LP**, Mariotti M, Salvestrini V, Scoccimarro E, Valzano M, Simontacchi G, Bonomo P, Lucidi S, Desideri I, Meattini I, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S1080-S1081, doi: 10.1016/S0167-8140(21)07767-7
<https://www.sciencedirect.com/science/article/pii/S0167814021077677>
 34. PD-0849 Concomitant Nivolumab and RT in metastatic kidney cancer. Benefit of ablative vs palliative approach
Francolini G, Di Cataldo V, Detti B, Loi M, Ghirardelli P, Vavassori V, Nicosia L, Alongi F, Triggiani L, La Mattina S, Allegra AG, Scoccimarro E, Aquilano M, Lucidi S, Valzano M, Peruzzi A, Morelli I, Mariotti M, Salvestrini V, Stocchi G, **Ciccone LP**, Desideri I, Livi L.
Radiotherapy and Oncology, Vol 161, Suppl 1, S683, doi: 10.1016/S0167-8140(21)07128-0
<https://www.sciencedirect.com/science/article/pii/S0167814021071280>
 35. PO-0997 Lack of CTV_P2 is not associated with a detrimental outcome in oropharyngeal cancer: a cohort study
Ciccone LP, Zani M, Scoccimarro E, Aquilano M, Banini M, Caprara L, Mariotti M, Salvestrini V, Becherini C, Desideri I, Marrazzo L, Pallotta S, Livi L, Bonomo P.
Radiotherapy and Oncology, Vol 161, Suppl 1, S829-S830, doi: 10.1016/S0167-8140(21)07448-X
<https://www.sciencedirect.com/science/article/pii/S016781402107448X>

36. May Different Treatment Volumes and Technical Approaches Have an Impact on Second Malignancies Risk?
 Francolini G, **Ciccone LP**, Di Cataldo V, Detti B, Simontacchi G, Loi M, Mangoni M, Desideri I, Meattini I, Livi L.
 J Clin Oncol. 2021 Sep 17: JCO2101790. doi: 10.1200/JCO.21.01790
<https://ascopubs.org/doi/pdf/10.1200/JCO.21.01790>
37. Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275)
 Francolini G, Loi M, Salvestrini V, Mangoni M, Detti B, Di Cataldo V, Aquilano M, Pinzani P, Salvianti F, Desideri I, Mariotti M, Garlatti P, Stocchi G, **Ciccone LP**, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L.
 Clin Exp Metastasis. 2021 Aug 19. doi: 10.1007/s10585-021-10118-7.
<https://link.springer.com/article/10.1007%2Fs10585-021-10118-7>
38. Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
 Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, Camerini A, Federici F, Meoni G, Caparello C, Turrini M, Rossi V, **Ciccone LP**, Pecora I, Fantechi B, Antonuzzo L, Giannarelli D, Baldini E.
 Anticancer Agents Med Chem. 2021 Jul 26. doi: 10.2174/1871520621666210727112212.
<https://www.eurekaselect.com/194998/article>
39. Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: a systematic review
 Desideri I, Becherini C, Belgioia L, Merlotti A, **Ciccone LP**, Franzese C, Loi M, De Felice F, Mazzola R, Caini S, Livi L, Bonomo P.
 Oral Oncol. 2021 May 24;119:105355. doi: 10.1016/j.oraloncology.2021.105355.
<https://www.sciencedirect.com/science/article/abs/pii/S1368837521001780?via%3Di%3Dhub>
40. Impact of COVID-19 on workload burden of a complex radiotherapy facility. Francolini G, Desideri I, Stocchi G, **Ciccone LP**, Salvestrini V, Garlatti P, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
 Radiol Med. 2021 May;126(5):717-721. doi: 10.1007/s11547-021-01338-8.
<https://link.springer.com/article/10.1007/s11547-021-01338-8>
41. ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.
 Francolini G, Garlatti P, Loi M, Detti B, Aquilano M, Allegra A, Guerrieri B, Salvestrini V, Pinzani P, Bellini C, Salvianti F, Stocchi G, **Ciccone LP**, Salvatore G, Sottili M, Di Cataldo V, Desideri I, Mangoni M, Meattini I, Livi L.
 Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021) 118-118. doi: 10.1200/JCO.2021.39.6_suppl.118
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.6_suppl.118
42. Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.

- Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, **Ciccone LP**, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M.
Lung Cancer. 2020 Dec; 150:123-131. doi: 10.1016/j.lungcan.2020.10.008.
[https://www.lungcancerjournal.info/article/S0169-5002\(20\)30658-9/fulltext](https://www.lungcancerjournal.info/article/S0169-5002(20)30658-9/fulltext)
43. Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery.
Scoccianti S, Perna M, Olmetto E, Delli Paoli C, Terziani F, **Ciccone LP**, Detti B, Greto D, Simontacchi G, Grassi R, Scoccimarro E, Bonomo P, Mangoni M, Desideri I, Di Cataldo V, Vernaleone M, Casati M, Pallotta S, Livi L.
Crit Rev Oncol Hematol. 2020 Nov 28;157:103184. doi: 10.1016/j.critrevonc.2020.103184.
<https://www.sciencedirect.com/science/article/abs/pii/S1040842820303206>
44. 412P Treatment patterns and selection criteria for advanced non-small cell lung cancer (NSCLC) patients unfit for platinum-based first-line therapy: Results of the MOON-OSS observational trial.
Camerini A, Del Conte A, Pezzuto A, Scotti V, Facchinetti F, **Ciccone LP**, Perna M, Sartori G, Puccetti C, Ricci A, Santo A, Tiseo M, Amoroso D. Annals of Oncology 31: S1403
doi: 10.1016/j.annonc.2020.10.406
[https://www.annalsofoncology.org/article/S0923-7534\(20\)42897-2/fulltext](https://www.annalsofoncology.org/article/S0923-7534(20)42897-2/fulltext)
45. Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration resistant prostate cancer undergoing 1 line treatment with abiraterone acetate (ARTO trial-NCT03449719)
Francolini G, Garlatti P, Detti B, Bruni A, Mantini G, Pergolizzi S, Borghetti P, D'Angelillo RM, Alongi F, Jereczek-Fossa BA, Franzese C, Tagliagambe A, Di Cataldo V, Aquilano M, Mariotti M, Salvestrini V, **Ciccone LP**, Stocchi G, Livi L.
European Urology Open Science 21:S150 doi: 10.1016/S2666-1683(20)36207-8
<https://www.sciencedirect.com/science/article/pii/S2666168320362078?via%3Dihub>
46. Comparison Between Accelerated Partial Breast Irradiation and Whole Breast Irradiation: APBI IMRT Florence Retrospective Analysis of Subjective, Objective and Patient- reported Cosmetic Outcomes
Meattini I, **Ciccone LP**, Lucidi S, Desideri I, Visani L, Perna M, Peruzzi A, Scotti V, Simontacchi G, Livi L.
International Journal of Radiation Oncology Biology Physics 108(3) doi: 10.1016/j.ijrobp.
[https://www.redjournal.org/article/S0360-3016\(20\)32326-9/fulltext](https://www.redjournal.org/article/S0360-3016(20)32326-9/fulltext)
47. PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis
Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Zerella MA, Gentile P, Bianciardi F, Allegrretta S, Detti B, Masi L, **Ciccone LP**, Bruni A, Ingrosso G, Mazzeo E, Trippa F, Lohr F, Livi L.
Radiotherapy and Oncology 152:S59-S60 doi: 10.1016/S0167-8140(21)00145-6
[https://www.thegreenjournal.com/article/S0167-8140\(21\)00145-6/pdf](https://www.thegreenjournal.com/article/S0167-8140(21)00145-6/pdf)

48. Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy. Desideri I, Francolini G, **Ciccone LP**, Stocchi G, Salvestrini V, Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
Support Care Cancer. 2020 Oct 2;1-7. doi: 10.1007/s00520-020-05793-3
<https://link.springer.com/article/10.1007/s00520-020-05793-3>

49. 617P Prospective assessment of AR splice variant and PSMA detection on circulating tumour cells of mCRPC patients: Preliminary results of PRIMERA trial (NCT04188275)
Francolini G, Salvestrini V, Loi M, Mangoni M, Detti B, Pinzani P, Salvianti F, Desideri I, Aquilano M, Mariotti M, Garlatti P, Stocchi G, **Ciccone LP**, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L.
Annals of Oncology Volume 31, Supplement 4, S538-S539. doi: 10.1016/j.annonc.2020.08.930
[https://www.annalsofoncology.org/article/S0923-7534\(20\)40926-3/fulltext](https://www.annalsofoncology.org/article/S0923-7534(20)40926-3/fulltext)

50. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Amerini A, Bearz A, De Carlo E, Zanelli F, Guitoli G, Garassino MC, **Ciccone LP**, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzuttilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M.
Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023.
[https://www.ejancer.com/article/S0959-8049\(20\)30096-4/fulltext](https://www.ejancer.com/article/S0959-8049(20)30096-4/fulltext)

51. Impact of metastases directed radiation therapy on CDK4/6 inhibitors dose reduction and treatment discontinuation for metastatic HR+/HER2- breast cancer (MBC).
Meattini I, Scoccimarro E, Saieva C, Desideri I, Visani L, Dominici L, Cerbai C, Aquilano M, **Ciccone LP**, Palmieri VE, Scotti V, Nori J, Bernini M, Orzalesi L, Sanchez L, Dieci MV, Bianchi S, Livi L.
Journal of Clinical Oncology 38(15_suppl):562-562 doi: 10.1200/JCO.2020.38.15_suppl.562
https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.562

52. Thermal Ablation versus SBRT in liver tumours: pros and cons
Loi M, Desideri I, Dominici L, Francolini G, Garlatti P, **Ciccone LP**, Stocchi G, Salvestrini V, Meattini I, Livi L.
Med Oncol. 2020 Apr 29;37(6):52. doi: 10.1007/s12032-020-01377-7.
<https://link.springer.com/article/10.1007/s12032-020-01377-7>

53. Artificial Intelligence in radiotherapy: state of the art and future directions Francolini G, Desideri I, Stocchi G, Salvestrini V, **Ciccone LP**, Garlatti P, Loi M, Livi L.
Med Oncol. 2020 Apr 22;37(6):50. doi: 10.1007/s12032-020-01374-w.
<https://link.springer.com/article/10.1007/s12032-020-01374-w>

54. Preliminary results of a prospective assessment of androgen receptor splice variants in mCRPC patients undergoing androgen receptor targeted agents.
Francolini G, Loi M, Detti B, Mangoni M, Desideri I, Muntoni C, **Ciccone LP**, Aquilano M, Pinzani P, Salvianti P, Lucidi S, Mariotti M, Garlatti P, Salvatore G, Sottili M, Livi L.
Journal of Clinical Oncology 38(6_suppl):246-246 doi: 10.1200/JCO.2020.38.6_suppl.246
https://ascopubs.org/doi/10.1200/JCO.2020.38.6_suppl.246

55. EP1.04-02 Predictors of Lung Toxicity in First Line Pembrolizumab for Advanced NSCLC: An Interim Analysis of PRELUTOX Study

Bonti V, Teriaca MA, Lavacchi D, Perna M, Caini S, Mazzoni F, Maragna V, Rosi E, Giannelli F, Cozzi D, Visani L, Calabrò A, Bartolucci M, **Ciccone LP**, Mariotti M, Flego N, Comin CE, Pezzulla D, Moroni C, Cavigli E, Bindi A, Caramia G, Meacci F, Miele V, Lavorini F, Voltolini L, Livi L, Scotti V, Ferrari K. Journal of Thoracic Oncology 14(10):S966-S967 doi: 10.1016/j.jtho.2019.08.2118
[https://www.jto.org/article/S1556-0864\(19\)32801-1/fulltext](https://www.jto.org/article/S1556-0864(19)32801-1/fulltext)

56. Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings.
Bonomo P, Desideri I, Loi M, **Ciccone LP**, Lo Russo M, Becherini C, Greto D, Simontacchi G, Pimpinelli N, Livi L.
Support Care Cancer. 2019 Aug;27(8):2957-2967. doi: 10.1007/s00520-018-4606-2.
<https://link.springer.com/article/10.1007%2Fs00520-018-4606-2>
57. OC-0276 Stereotactic radiosurgery plus immunotherapy or targeted therapy for brain metastases from NSCLC
Olmetto E, Delli Paoli C, **Ciccone LP**, Perna M, Grassi R, Scoccimarro E, Scoccianti S, Greto D, Desideri I, Simontacchi G, Marrazzo L, Arilli C, Casati M, Compagnucci A, Pecchioli G, Pallotta S, Livi L.
Radiotherapy and Oncology 133:S136-S137 doi: 10.1016/S0167-8140(19)30696
[https://www.thegreenjournal.com/article/S0167-8140\(19\)30696-6/pdf](https://www.thegreenjournal.com/article/S0167-8140(19)30696-6/pdf)
58. PO-148 Management of bio-radiation dermatitis in HNSCC: emphasizing the role of calcium alginate dressings
Bonomo P, Desideri I, Loi M, **Ciccone LP**, Lo Russo M, Becherini C, Visani L, Salvestrini V, Mariotti M, Pimpinelli N, Livi L.
Radiotherapy and Oncology 132:78-79 doi: 10.1016/S0167-8140(19)30314-7
[https://www.thegreenjournal.com/article/S0167-8140\(19\)30314-7/pdf](https://www.thegreenjournal.com/article/S0167-8140(19)30314-7/pdf)

Cari Colleghi

Propongo la mia candidatura come Consigliere AIRO nell'ambito del Gruppo di Studio Neuro-Oncologico con l'obiettivo di contribuire a sviluppare ulteriormente quanto già realizzato dai nostri colleghi in questi anni.

I miei principali obiettivi riguardano il completamento dell'analisi dei dati dei due studi già condivisi all'interno del GdS e coordinati dal centro dove lavoro:

- studio RABBIT-NEW (Radiochirurgia o Radioterapia stereotassica frazionata in associazione ai nuovi farmaci nel trattamento delle metastasi cerebrali da tumore della mammella), si tratta di uno studio retrospettivo multicentrico gestito dai gruppi di studio neuro-oncologico e mammella.
- studio Virtuose (V Twelve Or Something Else?) si tratta di uno studio retrospettivo multicentrico

Mi auguro di poter implementare ulteriormente il dialogo con gli altri gruppi di lavoro nazionali e internazionali che si occupano di NeuroOncologia.

Dr.ssa Lucia Pia Ciccone

SOC Radioterapia Oncologica

Ospedale Santa Maria Annunziata

Bagno a Ripoli, Firenze

Azienda USL Toscana Centro